{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:41:47Z","timestamp":1794206507037,"version":"4.8.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011495","name":"Massachusetts Life Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.metabol.2024.156082","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T08:16:46Z","timestamp":1732004206000},"page":"156082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables"],"prefix":"10.1016","volume":"163","author":[{"given":"Konstantinos","family":"Stefanakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geltrude","family":"Mingrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156082_bb0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0010","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared Cardiometabolic risk factors","volume":"79","author":"Muzurovi\u0107","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2024.156082_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156082_bb0020","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/apt.16016","article-title":"Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease","volume":"52","author":"Canbay","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156082_bb0025","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","article-title":"Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease","volume":"75","author":"Younes","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of Survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156082_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156082_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156082_bb0045","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.156082_bb0050","series-title":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease","author":"FDA","year":"2024"},{"key":"10.1016\/j.metabol.2024.156082_bb0055","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0060","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.156082_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154320","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156082_bb0070","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","article-title":"Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease","volume":"46","author":"Polyzos","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.metabol.2024.156082_bb0075","author":"FDA"},{"key":"10.1016\/j.metabol.2024.156082_bb0080","series-title":"Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide","author":"Boehringer-Ingelheim","year":"2024"},{"key":"10.1016\/j.metabol.2024.156082_bb0085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2024.04.036","article-title":"A turning point in hepatology? EASL reflects on the first approved drug for MASH","volume":"81","author":"Francque","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"issue":"24","key":"10.1016\/j.metabol.2024.156082_bb0095","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring Resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"S1542-3565","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156044","article-title":"Expanding diagnostic and therapeutic horizons for MASH: comparison of the latest and conventional therapeutic approaches","volume":"161","author":"Anastasiou","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156082_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study","volume":"147","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156082_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155694","article-title":"Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: a multicenter observational study","volume":"148","author":"Valenzuela-Vallejo","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156082_bb0115","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156082_bb0120","series-title":"Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)","author":"FDA","year":"2018"},{"key":"10.1016\/j.metabol.2024.156082_bb0125","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2024.156082_bb0130","unstructured":"ICH. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). international council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). 2016; Step 4 version. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf."},{"key":"10.1016\/j.metabol.2024.156082_bb0135","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156082_bb0140","first-page":"289","article-title":"An algorithm for the grading of activity in chronic hepatitis C","volume":"24","author":"Bedossa","year":"1996","journal-title":"The METAVIR Cooperative Study Group Hepatology"},{"key":"10.1016\/j.metabol.2024.156082_bb0145","first-page":"14","article-title":"Comparison of transient Elastography and point shear wave Elastography for analysis of liver stiffness: a prospective study","author":"Losurdo","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.metabol.2024.156082_bb0150","first-page":"7357","article-title":"Point shear wave elastography and vibration controlled transient elastography for estimating liver fibrosis in a cohort of liver transplant patients","volume":"24","author":"Valente","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.metabol.2024.156082_bb0155","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156082_bb0160","unstructured":"Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A. CatBoost: unbiased boosting with categorical features. Proceedings of the 32nd International Conference on Neural Information Processing Systems. Montr\u00e9al, Canada: Curran Associates Inc.; 2018. p. 6639\u201349."},{"key":"10.1016\/j.metabol.2024.156082_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000019","article-title":"Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017-2018","volume":"7","author":"Payne","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2024.156082_bb0170","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156082_bb0175","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","article-title":"Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients","volume":"30","author":"Kim","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.156082_bb0180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0185","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156082_bb0190","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0195","article-title":"Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD practice guideline","author":"Patel","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156082_bb0200","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/liv.15914","article-title":"Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-an individual participant data meta-analysis","volume":"44","author":"M\u00f3zes","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.156082_bb0205","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0210","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.10.038","article-title":"NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejim.2024.01.013","article-title":"Non-invasive testing and risk-stratification in patients with MASLD","volume":"122","author":"Zoncap\u00e8","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.metabol.2024.156082_bb0225","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11739-023-03441-2","article-title":"Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level","volume":"19","author":"Gabriel-Medina","year":"2024","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.metabol.2024.156082_bb0230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2020.06.040","article-title":"FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)","volume":"74","author":"Wu","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0240","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2021.08.017","article-title":"Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease 2013; implications for the clinical utility of the EASL NIT guideline","volume":"76","author":"van Kleef","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0245","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.156082_bb0250","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/jgh.12665","article-title":"Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Otgonsuren","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101145","article-title":"acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study","volume":"41","author":"Wu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2024.156082_bb0260","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction","volume":"167","author":"van Kleef","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.156082_bb0265","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156082_bb0270","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient Elastography scores to predict liver-related events in Steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2024.156082_bb0275","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156082_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.06.013","article-title":"AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD","volume":"21","author":"Pennisi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0285","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.156082_bb0290","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive assessment of liver fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb0295","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jnr.10012","article-title":"3-Ureidopropionate contributes to the neuropathology of 3-ureidopropionase deficiency and severe propionic aciduria: a hypothesis","volume":"66","author":"K\u00f6lker","year":"2001","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.metabol.2024.156082_bb0300","doi-asserted-by":"crossref","first-page":"14109","DOI":"10.1038\/s41598-022-17860-2","article-title":"Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular models","volume":"12","author":"Sullivan","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156082_bb0305","first-page":"13","article-title":"Plasma metabolite signatures in male carriers of genetic variants associated with non-alcoholic fatty liver disease","author":"Fernandes Silva","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.metabol.2024.156082_bb0310","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2024.156082_bb0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ijo.2014.53","article-title":"Mapping of the circulating metabolome reveals \u03b1-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease","volume":"39","author":"Rodr\u00edguez-Gallego","year":"2015","journal-title":"Int J Obes"},{"key":"10.1016\/j.metabol.2024.156082_bb1000","first-page":"120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","author":"Luukkonen","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2024.156082_bb2000","doi-asserted-by":"crossref","first-page":"155984","DOI":"10.1016\/j.metabol.2024.155984","article-title":"Longitudinal proteomics of leptin treatment in humans with acute and chronic energy deficiency-induced hypoleptinemia reveal novel, mainly immune-related, pleiotropic effects","volume":"159","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156082_bb3000","first-page":"1354","article-title":"Letter: Beyond advanced fibrosis-The critical need for assessing NITs performance in identifying F2-F3 fibrosis","volume":"59","author":"McPherson","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156082_bb4000","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.11.009","article-title":"Using NIS2+\u2122 to identify at-risk MASH in clinical trials","volume":"80","author":"Lai","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156082_bb5000","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.10.038","article-title":"NIS2+\u2122 as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952400310X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952400310X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:47:37Z","timestamp":1738975657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952400310X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":68,"alternative-id":["S002604952400310X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156082","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156082"}}